#Aurora Cannabis #Edmonton #Curaleaf #Takeover Bids

Aurora Cannabis Inc. Responds to Curaleaf's Take-Over Bid

In a recent statement, Aurora Cannabis Inc. (NASDAQ: ACB) situated in Canada, addressed a press release from Curaleaf Holdings, Inc., which announced an unsolicited take-over offer for the outstanding common shares of Aurora. The proposed bid is said to involve an apparent compensation of US$4.00 per share, a combination of shares from Curaleaf and cash.

Aurora confirmed that it had received communications from Curaleaf about acquisition proposals, with significant detail only emerging in letters dated July 2026. Intriguingly, the proposal offers a maximum value considerably less than past trading prices of Aurora shares, which raises concerns about its potential benefits for Aurora stakeholders.

The bid is unsolicited, and Aurora's board took it upon themselves to carefully analyze previous proposals from Curaleaf and consider alternate strategic alternatives. Furthermore, the successful acquisition of the Safari Flower Company earlier serves to bolster Aurora's medical cannabis platform, highlighting an empowering strategic move towards sustainable growth and long-term shareholder value.

The leadership of Aurora has stated its willingness to engage in discussions, as highlighted by correspondences between Aurora's lead independent director and Curaleaf’s CEO. Aurora seems open to an ongoing dialogue while remaining committed to executing its already established business strategies.

Aurora intends to form a special committee of independent directors to evaluate Curaleaf's proposal thoroughly. They will strategically determine the best course of action for the company and its stakeholders while inherently continuing regular business operations, signalling stability during this period of negotiation.

It’s critical to note that Aurora's shareholders need not act at this moment. No decisions regarding Curaleaf's proposal have been finalized, and Aurora aims to maintain its focus on advancing its existing operations. Shareholders will be informed about any developments only if necessary.

Aurora's Position in the Medical Cannabis Market

As a global leader in medical cannabis, Aurora’s commitment to enhancing the quality of lives through scientific innovation and patient care has set a high standard. The company distributes its products throughout various medical markets in Canada, Europe, Australia, and New Zealand under several trusted brands, including Aurora® and MedReleaf®. Their state-of-the-art facilities in Canada and Germany further ensure the production of premium quality cannabis products that align with their mission of “Opening the World to Cannabis™.”

Aurora's shares continue to be traded under the ticker